全文获取类型
收费全文 | 173篇 |
免费 | 19篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 8篇 |
妇产科学 | 2篇 |
基础医学 | 51篇 |
口腔科学 | 2篇 |
临床医学 | 16篇 |
内科学 | 56篇 |
皮肤病学 | 3篇 |
神经病学 | 14篇 |
特种医学 | 2篇 |
外科学 | 10篇 |
综合类 | 3篇 |
预防医学 | 1篇 |
药学 | 2篇 |
中国医学 | 1篇 |
肿瘤学 | 23篇 |
出版年
2023年 | 4篇 |
2022年 | 5篇 |
2021年 | 6篇 |
2020年 | 7篇 |
2019年 | 11篇 |
2018年 | 6篇 |
2017年 | 5篇 |
2016年 | 9篇 |
2015年 | 8篇 |
2014年 | 11篇 |
2013年 | 13篇 |
2012年 | 11篇 |
2011年 | 12篇 |
2010年 | 11篇 |
2009年 | 12篇 |
2008年 | 15篇 |
2007年 | 10篇 |
2006年 | 10篇 |
2005年 | 9篇 |
2004年 | 5篇 |
2003年 | 4篇 |
2002年 | 3篇 |
2001年 | 4篇 |
2000年 | 1篇 |
1997年 | 2篇 |
1995年 | 1篇 |
排序方式: 共有195条查询结果,搜索用时 703 毫秒
1.
Capillary array electrophoresis (CAE) is a novel technique, which allows for high throughput analysis of DNA fragments. When screening for mutations in whole populations or large patient groups it is necessary to have robust and well-characterized setups for high throughput analysis. For large-scale mutation screening, we have developed procedures for single strand conformation polymorphism (SSCP) assays using CAE (CAE-SSCP) whereby we may increase both the sensitivity and the throughput compared to conventional SSCP analysis. In this study we have validated CAE-SSCP by 1) comparing detection by slab-gel based SSCP with CAE-SSCP of mutations in the MYH7, MYL2, and MYL3 genes encoding sarcomere proteins from patients suffering from hypertrophic cardiomyopathy; and 2) by constructing a series of 185 mutants having substitution mutations, as well as insertion/deletion mutations, or some combinations of these, in different sequence contexts in four exons and different positions relative to the end of the amplicon (three from the KCNQ1 gene, encoding a cardiac potassium channel, and one from the TNNI3 gene encoding cardiac troponin I). The method identified 181 out of 185 mutations (98%), and the data suggest that the position of mutation in the fragment had no effect on the sensitivity. Analysis of the specificity of the method showed that only very few mutants could not be distinguished from each other and there were no false positives. 相似文献
2.
3.
Clint L. Miller Amy R. Kontorovich Ke Hao Lijiang Ma Conrad Iyegbe Johan L.M. Björkegren Jason C. Kovacic 《Journal of the American College of Cardiology》2021,77(20):2531-2550
In this second of a 5-part Focus Seminar series, we focus on precision medicine in the context of vascular disease. The most common vascular disease worldwide is atherosclerosis, which is the primary cause of coronary artery disease, peripheral vascular disease, and a large proportion of strokes and other disorders. Atherosclerosis is a complex genetic disease that likely involves many hundreds to thousands of single nucleotide polymorphisms, each with a relatively modest effect for causing disease. Conversely, although less prevalent, there are many vascular disorders that typically involve only a single genetic change, but these changes can often have a profound effect that is sufficient to cause disease. These are termed “Mendelian vascular diseases,” which include Marfan and Loeys-Dietz syndromes. Given the very different genetic basis of atherosclerosis versus Mendelian vascular diseases, this article was divided into 2 parts to cover the most promising precision medicine approaches for these disease types. 相似文献
4.
Chauffrey L Chamouni P Bégarin L Benhamou Y Cailleux N Borg JY Callat MP Schlegel N Lévesque H 《La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne》2012,33(2):99-102
Introduction
The MYH9 syndrome is a group of rare autosomal dominant platelet disorders associating in most of the cases a macrothrombocytopenia and characteristic leukocyte inclusions. Clinical features may include renal, visual, or hearing impairment. The bleeding tendency is usually moderate.Case report
We report a 28-year-old-man, with an auto-immune haemolytic anaemia associated with a MYH9 syndrome.Conclusion
To our knowledge, this is the first report of such an association. 相似文献5.
6.
Nielsen M Hes FJ Nagengast FM Weiss MM Mathus-Vliegen EM Morreau H Breuning MH Wijnen JT Tops CM Vasen HF 《Clinical genetics》2007,72(5):427-433
A small fraction of families with familial adenomatous polyposis (FAP) display an attenuated form of FAP (AFAP). We aimed to assess the presence of germline mutations in the MUTYH and adenomatous polyposis coli (APC) genes in AFAP families and to compare the clinical features between the two causative genes. Families with clinical AFAP were selected from the Dutch Polyposis Registry according to the following criteria: (a) at least two patients with 10-99 adenomas diagnosed at age >30 years or (b) one patient with 10-99 adenomas at age >30 years and a first-degree relative with colorectal cancer (CRC) with a few adenomas, and, applying for both criteria, no family members with more than 100 polyps before the age of 30 years. All probands were screened for germline mutations in the APC and MUTYH genes. Twenty-five of 315 Dutch families with FAP (8%) met our criteria for AFAP. These families included 146 patients with adenomas and/or CRC. Germline APC mutations were identified in nine families and biallelic MUTYH mutations in another nine families. CRC was identified at a mean age of 54 years (range 24-83 years) in families with APC and at 50 years (range 39-70 years) in families with MUTYH (p = 0.29). APC and biallelic MUTYH mutations are responsible for the majority of AFAP families. Based on our results and those reported in the literature, we recommend colonoscopy once every 2 years in AFAP families, starting surveillance from the late teens in APC mutation carriers and from age 20-25 years in biallelic MUTYH mutation carriers. 相似文献
7.
肥厚型心肌病(hypertrophic cardiomyopathy,HCM)是儿童中最常见的单基因遗传性心肌病。肌节基因[β-肌球蛋白重链(cardiac beta-myosin heavy chain,MYH7)、MYBPC3等基因]突变是HCM最常见的遗传学病因,其中以MYH7基因突变最常见,占30%~50%。MYH7基因突变具有受环境因素影响、可合并多个基因变异,以及年龄依赖的外显率等特点,使患儿临床表型不一或重叠,包括多种心肌病和骨骼肌疾病。目前关于MYH7基因突变导致儿童HCM的发病机制、病程及预后尚不明确。该文通过总结MYH7基因突变导致HCM可能的发病机制、临床表型及治疗,以期有利于患儿的精准预后评估、个体化管理及治疗。 相似文献
8.
Loredana Bury Karyn Megy Jonathan C. Stephens Luigi Grassi Daniel Greene Nick Gleadall Karina Althaus David Allsup Tadbir K. Bariana Mariana Bonduel Nora V. Butta Peter Collins Nicola Curry Sri V. V. Deevi Kate Downes Daniel Duarte Kim Elliott Emanuela Falcinelli Bruce Furie David Keeling Michele P. Lambert Rachel Linger Sarah Mangles Rutendo Mapeta Carolyn M. Millar Christopher Penkett David J. Perry Kathleen E. Stirrups Ernest Turro Sarah K. Westbury John Wu NIHR BioResource Keith Gomez Kathleen Freson Willem H. Ouwehand Paolo Gresele Ilenia Simeoni 《Human mutation》2020,41(1):277-290
The heterogeneous manifestations of MYH9‐related disorder (MYH9‐RD), characterized by macrothrombocytopenia, Döhle‐like inclusion bodies in leukocytes, bleeding of variable severity with, in some cases, ear, eye, kidney, and liver involvement, make the diagnosis for these patients still challenging in clinical practice. We collected phenotypic data and analyzed the genetic variants in more than 3,000 patients with a bleeding or platelet disorder. Patients were enrolled in the BRIDGE‐BPD and ThromboGenomics Projects and their samples processed by high throughput sequencing (HTS). We identified 50 patients with a rare variant in MYH9. All patients had macrothrombocytes and all except two had thrombocytopenia. Some degree of bleeding diathesis was reported in 41 of the 50 patients. Eleven patients presented hearing impairment, three renal failure and two elevated liver enzymes. Among the 28 rare variants identified in MYH9, 12 were novel. HTS was instrumental in diagnosing 23 patients (46%). Our results confirm the clinical heterogeneity of MYH9‐RD and show that, in the presence of an unclassified platelet disorder with macrothrombocytes, MYH9‐RD should always be considered. A HTS‐based strategy is a reliable method to reach a conclusive diagnosis of MYH9‐RD in clinical practice. 相似文献
9.
10.
Megumi Mathison Vivek P. Singh Maria J. Chiuchiolo Deepthi Sanagasetti Yun Mao Vivekkumar B. Patel Jianchang Yang Stephen M. Kaminsky Ronald G. Crystal Todd K. Rosengart 《The Journal of thoracic and cardiovascular surgery》2017,153(2):329-339.e3